Eagle Pharmaceuticals

Trial and FDA signals

• FDA complete response letter Received an FDA complete response letter (NDA 220045, letter dated Apr 13, 2026). FDA NDA 220045 (Apr 13, 2026)
  Evidence (1 event)

  • Apr 13, 2026 · FDA NDA 220045
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Eagle Pharmaceuticals, Inc. Attention: Janis A. Picurro Senior Vice President, Regulatory Affairs Woodcliff Lake, NJ (street omitted) Dear Janis Picurro: Please ref

Job counts as of Oct 18, 2026. All trial and FDA signals